Status:
TERMINATED
Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation
Lead Sponsor:
Centre Oscar Lambret
Collaborating Sponsors:
University Hospital, Lille
Conditions:
Nsclc
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Condorde main objective is to evaluate the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed on ctDNA after liquid biopsy. EGFR status will b...
Detailed Description
Newest therapeutic breakthrough are often based on molecular analysis of tumoral tissue before treatment initiation or after emergence of resistance. Tumoral tissue is commonly obtained by biopsy. How...
Eligibility Criteria
Inclusion
- At least 18 years
- Metastatic lung carcinoma
- With: - EGFR gene mutation
- Or at least 2 predictive factors of addictive mutation (Women, non smocking or cessation \> 3 years, Asiatic, lung adenocarcinoma)
- Eligible for 1st line treatment
- Performance status ≤ 3
- Available tumor sample or tumor reachable for biopsy
- With informed and signed consent
- Affiliation to the National Social Security System
Exclusion
- Previous radiotherapy treatment in months preceding initials samples
- Pregnant or breastfeeding women
- Patient not able to give consent or unwilling to provide consent
Key Trial Info
Start Date :
July 7 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 13 2021
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT03265496
Start Date
July 7 2016
End Date
April 13 2021
Last Update
October 22 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Oscar Lambret
Lille, France, 59020
2
CHRU Lille
Lille, France, 59037